Skip to main content
Clinical Trials/NCT02410031
NCT02410031
Completed
Not Applicable

Study to Evaluate Physician Knowledge of Safety and Safe Use Information for Diane-35 and Its Generics in Europe: An Observational Post-Authorisation Safety Study

Bayer0 sites759 target enrollmentJune 26, 2015

Overview

Phase
Not Applicable
Intervention
Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)
Conditions
Acne Vulgaris
Sponsor
Bayer
Enrollment
759
Primary Endpoint
The knowledge of the physician concerning Diane-35
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians with recent experience in prescribing Diane-35 or its generics in a total of five European countries. The primary objective of this study is to measure physician knowledge and understanding of the key information contained in the Diane-35 educational material: Patient information card, and Prescribers' Checklist.

Specifically, the following objectives will be addressed:

  • Investigate whether physicians have received any educational material related to Diane-35 or its generics
  • Assess physicians' knowledge and understanding of key safety information pertaining to the patient information card
  • Assess physicians' knowledge and understanding of key safety information pertaining to the following areas:
  • Contraindications relevant to thromboembolism
  • Risk factors for thromboembolism
  • Signs and symptoms of thromboembolism
Registry
clinicaltrials.gov
Start Date
June 26, 2015
End Date
March 4, 2016
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Bayer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Physicians eligible to participate will have recently prescribed (e.g., within previous 6 months) Diane-35 or its generics

Exclusion Criteria

  • Not provided

Arms & Interventions

Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)

Prescribers of Diane-35 who agree and fulfill the criteria inclusion to participate in the survey

Intervention: Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)

Outcomes

Primary Outcomes

The knowledge of the physician concerning Diane-35

Time Frame: Day1

The knowledge will be assessed based on a questionnaire with 22 questions which wil assess physician knowledge on key information contained in the Diane-35 educational material including patient information card, prescribers' checklist

Similar Trials